Related Experiment Videos

Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a

Kazunori Toyoda1, Masahiro Yasaka, Kazunori Iwade

  • 1Cerebrovascular Division, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan. toyoda@ hsp.ncvc.go.jp

Stroke
|April 5, 2008
PubMed

Insights

Patients on dual antithrombotic therapy, especially warfarin plus an antiplatelet agent, face a higher risk of bleeding events. This study highlights the importance of monitoring bleeding risks in Japanese patients taking oral antithrombotic agents.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Hemorrhagic stroke incidence is higher in Japan than in Western countries.
  • Oral antithrombotic agents are widely used for stroke and cardiovascular diseases.
  • Understanding bleeding risks in Japanese patients is crucial.

Purpose of the Study:

  • To determine the incidence and severity of bleeding events in Japanese patients on oral antithrombotic agents.
  • To compare bleeding event rates across different antithrombotic treatment regimens.
  • To assess the independent risk factors for bleeding events.

Main Methods:

  • A prospective, multicenter, observational study involving 4009 patients.
  • Patients were categorized into four treatment groups: single antiplatelet, dual antiplatelet, warfarin, and warfarin plus antiplatelet.
  • Life-threatening or major bleeding events were tracked using the MATCH trial definition.

Main Results:

  • The annual incidence of major bleeding events ranged from 1.21% to 3.56% across treatment groups.
  • Dual antithrombotic therapy, particularly warfarin plus antiplatelet agents, showed a significantly higher risk of bleeding (P<0.001).
  • Adding an antiplatelet to warfarin increased the risk of major bleeding (RR=1.76), and dual antiplatelet therapy increased any bleeding (RR=1.37).

Conclusions:

  • Bleeding event incidence in Japan was comparable to Western countries despite differing study designs.
  • Dual antithrombotic therapy is independently associated with an increased risk of bleeding events.
  • Risk stratification and careful monitoring are essential for patients on dual antithrombotic therapy.
Abstract

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...